Quarterly report pursuant to Section 13 or 15(d)

Inventory

v3.22.2.2
Inventory
9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventory

(6) Inventory

Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. The Company expensed costs related to inventory within the Research and development line in the Consolidated Statements of Operations until it received approval from the FDA to market a product, at which time the Company commenced capitalization of costs relating to that product. Adjustments to inventory are determined at the raw material, sub-assemblies and finished goods levels to reflect obsolescence or impaired balances.

Inventory consists of the following:

 

 

 

September 30, 2022

 

 

December 31, 2021

 

Raw materials

 

$

26

 

 

$

53

 

Sub-assemblies

 

 

4,015

 

 

 

4,656

 

Finished goods

 

 

1,630

 

 

 

645

 

 

 

 

5,671

 

 

 

5,354

 

Provision for inventory obsolescence

 

 

(1,194

)

 

 

(352

)

Inventory

 

$

4,477

 

 

$

5,002